Exenatide for Myocardial Protection During Reperfusion Study

A phase 2 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 198 participants.

Also called NCT01938235

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 198 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT01938235
Start date
(registry gives no type) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Canada (from the registry)
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT01938235. Randomized; quadruple masking; primary purpose treatment. Start 2014-02 (registry gives no type); primary completion 2017-07 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Exenatide for Myocardial Protection During Reperfusion Study
Acronym
EMPRES
Intervention (Drug)
Exenatide
Intervention (Drug)
Placebo
Lead sponsor
University Health Network, Toronto (class: other)
Collaborator
AstraZeneca (class: industry)

Record details

Record id
cardio:ct-nct01938235
Content hash
d08add24689348fea07dc2348c482b64e0a17ff6dcbee79bbf88a903852a801c